After a challenging 2014.

Boehringer Ingelheim positioned for potential growth with product launches With numerous advertising authorisations for product and medicines launches in 2014, the research-driven pharmaceutical company Boehringer Ingelheim is currently positioned for upcoming growth. After a challenging 2014, the concentrate for us now could be on launching numerous extra services and on our profitability, stated Professor Andreas Barner, Chairman of the Table of Controlling Directors of Boehringer Ingelheim, at the Annual Press Meeting. We could actually submit a lot of compounds for advertising authorisation in 2014 and, with study and development expenditure amounting to near 2 where to buy dapoxetine online .7 billion euros, we’ve invested once later on again.

?priligy reviews

Because it was founded in 1885, the family-owned business has been focused on researching, developing, advertising and manufacturing novel medicines of high therapeutic value to get human being and veterinary remedies. In 2011, Boehringer Ingelheim achieved net sales around 13.2 billion Euro. As a respected biopharmaceutical contract producer with an increase of than 35 years of experience – the business has taken 19 biopharmaceutical items to market.. Boehringer Ingelheim enters strategic collaboration contract to aid Molecular Partner’s proprietary pipeline Boehringer Ingelheim’s biopharmaceutical agreement production business and Molecular Companions have entered right into a strategic production collaboration.

Other entries from category "endocrinology":

Random entries